标题：尤瑞克林治疗急性脑梗死的疗效及安全性评价

      作者：谭少华，林耀波，刘 聪，李丽娟，李少梅
    (广州市番禺区中心医院神经内科，广东 广州 511400)

      卷次： 2013年24卷16期

      【摘要】 目的 评价注射用尤瑞克林对急性脑梗死的临床疗效及安全性。方法 根据1995年第四届全国
脑血管病会议制订的诊断标准，选取急性脑梗死患者100例，入选病例随机分为两组各50例，对照组患者给予缺
血性脑卒中基础治疗；治疗组患者除给予基础治疗外，予注射用尤瑞克林0.15 PNA，分别于治疗前、治疗7 d及治
疗14 d行NIHSS评分，并对治疗前后肝肾功能、凝血功能及出血事件作比较。结果 治疗7 d两组NIHSS评分差
异无统计学意义(P>0.05)；治疗14 d治疗组NIHSS评分较对照组明显下降，差异有统计学意义(P<0.05)；两组肝
肾功能损害、凝血功能及出血事件差异无统计学意义(P>0.05)。结论 尤瑞克林治疗急性脑梗死患者安全有效，
优于单纯使用缺血性脑卒中基础治疗。

      【关键词】 尤瑞克林；脑梗死；临床疗效；安全性

      【中图分类号】 R743.33 【文献标识码】 A 【文章编号】 1003—6350（2013）16—2350—02


Clinical efficacy and safety of urinary kallidinogenase injection in patients with acute cerebral infarction.
TAN
Shao-hua, LIN Yao-bo, LIU Cong, LI Li-juan, LI Shao-mei. Department of Neurology, Guangzhou Panyu Central
Hospital, Guangzhou 511400, Guangdong, CHINA

【Abstract】 Objective To evaluate the clinical efficacy and safety of urinary kallidinogenase injection
in patients with acute cerebral infarction. Methods One hundred patients with acute cerebral infarction were
included in this trial, which were randomly divided into two groups. Patients in the control group (n=50) were
treated with basic therapy, while those in the treatment group (n=50) were treated with urinary kal1idinogenase
injection and basic therapy. NIHSS score were evaluated before treatment, 7 days and 14 days after treatment,
respectively. Hepatic function, renal function, coagulation function and hemorrhagic event were recorded be-
fore and after treatment. Results No significant difference was in NIHSS sore found 7 d after treatment (P>
0.05), while 14 days after treatment, NIHSS score in the treatment group was significantly lower than that in
the control group (P<0.05). No significant difference was found before and after treatment on hepatic, renal, co-
agulation impairment and hemorrhagic event (P<0.05). Conclusion Urinary kallidinogenase injection is effec-
tive and safe for patients with acute cerebral infarction, which is better than single use of basic therapy.

      【Key words】 Urinary kal1idinogenase; Cerebral infarction; Clinical efficacy; Safety